check_circleStudy Completed
Anticoagulation
Bayer Identifier:
18984
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Accessibility to new drugs versus SOC in Sweden
Trial purpose
The healthcare system in Sweden is publicly funded and aims to provide equal access to care irrespective of socioeconomic status. This includes ensuring equity in drug treatment. Socioeconomic disparities have been shown to influence patient management and health outcomes in certain Swedish populations. The Swedish Board of Health and Welfare has stated that the prescription of new drugs, which are more expensive than generic standard of care drugs, might be influenced by patients’ socioeconomic status.
To evaluate the association between socioeconomic factors and use of a DOAC (rivaroxaban, dabigatran, or apixaban) or standard of care (warfarin) in patients with NVAF in Sweden.
To evaluate the association between socioeconomic factors and use of a DOAC (rivaroxaban, dabigatran, or apixaban) or standard of care (warfarin) in patients with NVAF in Sweden.
Key Participants Requirements
Sex
AllAge
18 - N/ATrial summary
Enrollment Goal
68056Trial Dates
June 2016 - June 2017Phase
Phase 4Could I Receive a placebo
NoProducts
Xarelto (Rivaroxaban, BAY59-7939)Accepts Healthy Volunteer
NoWhere to participate
Status | Institution | Location |
---|---|---|
Completed | Stockholm, Sweden |
Primary Outcome
- Correlation between socioeconomic factors and use of DOACs vs. Warfarin (as identified from the LISA database before the index date)Between 1 December 2011 and 31 December 2014; Socioeconomic factors: - Occupation - Education - Income - Family status - Immigrant statusdate_rangeTime Frame:approximately 3 years
Secondary Outcome
- Secular trends in the correlation between socioeconomic factors and use of DOACs (vs. warfarin) - Trends based on the date of prescription by yearBetween 1 December 2011 and 31 December 2014; Relationship between socioeconomic factors and access to newly marketed drugs (DOACs as one class which includes Rivaroxaban, Dabigatran and Apixaban) versus standard of care (warfarin) for different calender period.date_rangeTime Frame:approximately 3 years
Trial design
Trial Type
ObservationalIntervention Type
DrugTrial Purpose
N/AAllocation
N/ABlinding
N/AAssignment
N/ATrial Arms
N/A